Eleven Biotherapeutics: Clinical Update (Eleven Biotherapeutics) - Aug 13, 2015 - Anticipated topline data from first P3 trial EBI-005-AC-2 (NCT02492321) for moderate-to-severe allergic conjunctivitis in Q1 2016; Anticipated initiation of second P3 trial for allergic conjunctivitis in H2 2016
Anticipated new P3 trial • Anticipated P3 data: top line • Immunology
|